A Fully Integrated Cancer Company.
|
|
- Melvin West
- 5 years ago
- Views:
Transcription
1 A Fully Integrated Cancer Company. Jefferies 2015 Healthcare Conference June 2, 2015 Robert Mulroy, President & CEO
2 Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts, they are forwardlooking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack s strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, will, would, could, should, continue, and similar expressions. In this presentation, Merrimack s forward-looking statements include, among others, statements about the New Drug Application that Merrimack submitted to the FDA, the market opportunity and potential eligible patient populations for its investigational therapeutics, Merrimack s plans to commercialize MM-398, the potential timing and amounts of payments under its partnership with Baxter, the sufficiency of data from Merrimack s Phase 2 clinical trial of MM-302 to support an application for accelerated approval by the FDA, the potential effectiveness and safety profile of Merrimack s investigational therapeutics in certain patient populations or subpopulations, Merrimack s ability to develop predictive diagnostics, the timing of initiation and completion of new clinical trials, the timing of availability of clinical trial data and Merrimack s ability to translate clinical data into future clinical success. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, development progress of Merrimack s companion diagnostics, availability of funding sufficient for Merrimack s foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other matters that could affect the availability or commercial potential of Merrimack s drug candidates or companion diagnostics. Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack s views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack s business in general, see the Risk Factors section of Merrimack s Quarterly Report on Form 10- Q filed with the Securities and Exchange Commission (SEC) on May 7, 2015 and other reports Merrimack files with the SEC. 2
3 A Fully Integrated Cancer Company Systems Foundation Precision Diagnostics Clinical Translation Integrated Medicine Targeted Therapies 3
4 Recent Progress/Highlights MM-398 NDA Filing Robust Ph3 data in post-gem pancreatic cancer Fast Track rolling NDA submission completed in April Preparing for US approval and launch targeting ~19,000 patients Baxter Partnership Entered into a $970M Ex-US partnership for MM-398 $250M near term funding expansion/commercial Development plan for 1L pancreatic and gastric MM Ph2 BM+ patients w/ HRs between Registration path planned in breast and lung cancer Targeting >300,000 HRG+ BC & NSCLC patients MM-302 Launched Ph2 3L HER2+ breast cancer trial Designed for potential Accelerated Approval application Targeting ~8,000 US patients post T-DM1 4
5 Systems-Based Drug Discovery Gene Protein Network Network dynamics govern cell decisions Systems dynamics is a way to evolve our understanding of cancer and our ability to develop targeted therapies Predictive models enable more precise targeting and the development of diagnostics Simulations inform the engineering of drugs and the understanding of their pharmacodynamics Paired with deep technological expertise, this approach enables rapid development of new therapies with a strong clinical rationale 5
6 Systems-Driven Clinical Insights Resistance Exposure Synergy Network Dx uanatomy Dx 6
7 Drugs Engineered to Specific Cancer Biology PC Phase 1 Phase 2 Phase 3 MM-310 undisclosed MM-131 c-met & EpCAM DX-929 Nano-imaging agent MM-151 EGFR MM-121 ErbB3 MM-302 nano-doxorubicin MM-111 ErbB2-ErbB3 MM-302 MM-141 nano-doxorubicin IGF1R-ErbB3 MM-398 irinotecan liposome injection nanoliposomes antibody-targeted nanoliposomes mab bi-specific antibodies oligoclonal MM-398 MM-302 MM-310 MM-121 MM-141 MM-131 MM-151 7
8 Rational Development of Integrated Medicines Systems Diagnostics Network Inhibitors Targeted Cytotoxics MACK IM Regimens Network Activation: Dx121 Dx Dx141 Dx Deposition: FMX Dx
9 Nanotherapeutics Designed for Protected Delivery and Prolonged Exposure Nano Target Payload MM-398 MM-302 MM-310 Macrophages HER2 TBA Tumor Antigen 80,000 CPT-11; locally activated SN-38 30,000 Doxorubicin; Internalized TBA cytotoxic; Locally activated MM-398: 300-fold Increase in Exposure t 1/2 (h) AUC (µg*h/ml) CPT MM
10 MM-398 Overview Nanoliposomal encapsulation of irinotecan Combination achieved OS endpoint in Ph3 post-gem metastatic panc cancer trial Fast Track and Orphan Drug designations Patients with high unmet need No clear standard of care Rolling NDA submission completed in April; preparing to commercialize in US Ex-US partnership with Baxter 10
11 MM-398 Ph3 Results Met clinical endpoints with MM FU/LV combination Overall Survival: 0.67 HR (p=0.012) PFS: 0.56 HR (p=0.0001) Overall treatment response: 16% vs. 1% (p=<0.001) 12-week PFS rate: 57% vs 26% CA19-9 tumor marker response: 36% vs 12% Acceptable risk/benefit profile Most frequent grade 3+ AEs include neutropenia, fatigue, and GI effects 1) Protocol-defined primary analysis data cut (14Feb2014, after 305 events). Survival follow-up is ongoing and the final results will be reported once all patients are off treatment and at least 90% events have taken place. 2) Protocol-defined primary analysis data cut (14Feb2014, after 305 events). Per protocol population was defined as patients who received at least 80% of the protocol defined treatment during the first 6 weeks of treatment and did not have protocol deviations related to inclusion/exclusion criteria, receiving prohibited therapies or not receiving treatment as randomized. Overall Survival Proportion # at risk: Overall Survival Proportion Intent to Treat (ITT 1 ) Population Median OS, Months (95% CI) MM FU/LV 6.1 ( ) 5-FU/LV 4.2 ( ) Unstratified HR: 0.67 ( ) p = Stratified HR: 0.57 ( ) p = Per Protocol Time from randomization (PP 2 ) (months) Population Median OS, Months (95% CI) 0.9 MM FU/LV 8.9 ( ) FU/LV 5.1 ( ) Stratified HR: 0.47 ( ) p = Time from randomization (months) 11
12 Post-Gemcitabine PanC Opportunity Positive Post-Gemcitabine Metastatic Patient Dynamics Patients receive gemcitabine in all lines of therapy Differentiated from secondline therapy ~19,000 eligible patients in US Post-gemcitabine treatment rates growing Significant Worldwide Opportunity Annually (000 s) Diagnosed Incidence A B C US EU28 JP First-line Second-line Third-line Total Eligible
13 % Share* % Polled Oncologists* New Standard of Care Opportunity Current 2L Practice Oncologists View of MM % 2% Other 8% Gem/Tarceva 80% 80% 20% Gem Mono 60% 60% 40% 20% Gem/Abraxane 20% Capecitabine 40% 20% 60% 37% 3% 20% 0% 20% FOLFOX 10% FOLFIRINOX 0% Superior to Some or All Equivalent Slightly Inferior MM-398 regimen viewed more favorably than FOLFOX across dimensions of efficacy, safety and dosing* *Source: Clarion TPP Analysis, July,
14 Best Change in Tumor Lesion Size MM-398 Diagnostic Approach with Ferumoxytol * Pre FMX MRI 24 hours post FMX MRI Presented at ICSB 2014 and AACR 2014 grow 9 patients 31 lesions 6 indications *The FDA has approved ferumoxytol (Feraheme, AMAG Pharmaceuticals) for intravenous use as an iron replacement product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The use of ferumoxytol in the pilot study mentioned above has not been approved by the FDA and is for clinical investigational studies only. More FMX uptake stable shrink 14
15 MM-398 Path Forward & Next Steps Regulatory Rolling NDA submission completed in April Received Fast Track and Orphan Drug designations; have requested Priority Review Commercial Expansion Experienced team preparing for US launch Geographic concentration of pancreatic cancer centers enables focused commercial team Third-party market research shows favorable oncologist impression of MM-398+5FU/LV profile Planning trial initiations in front-line pancreatic and HER2-negative gastric ISTs in glioma and Ewing s sarcoma Deposition diagnostic development 15
16 MM-302 Design Integrates Proven Therapeutic Approaches in HER2+ MBC MM-302 antibody liposome conjugate: delivers a large chemotherapy payload 1. HER2 target validated in HER2+ MBC 2. Doxorubicin approved chemotherapy with greatest activity in HER2+ MBC 3. Liposomal Encapsulation aims to avoid cardiotoxicity of doxorubicin 16
17 Significant Need for Improved Treatment Options in Late-line HER2+ MBC Number of Patients (per year in US)* Standard of Care Therapy 1 st Line 2 nd Line 3 rd, 4 th Line or greater 8,800 7,500 8,500 Pertuzumab + trastuzumab + taxane T-DM1 No clear SOC Median PFS 18 months 1 10 months months 3 Clinical Outcome ~30% progress in 12 months ~20% don t respond ~30% progress in <6 months ~55% don t respond Rapid progression ~90% don t respond 1 CLEOPATRA, Baselga, et al EMELIA, Verma, et al TH3RESA, Krop, et al 2014 *Taken from Decision Resources, 2014 report 17
18 MM-302 Shows Promising Ph1 Activity MM-302 Phase 1 Efficacy (MM-302 alone, with trastuzumab and with trastuzumab and cyclophosphamide) Overall Median PFS (n=62) 7.6 mo Greatest activity in anthracycline-naïve patients (n= 25 in anthracycline-naïve patients) ORR = 24% (6/25) PFS = 11 mo Overall population received a median of 4 prior lines of therapy Includes only patients dosed at therapeutic doses ( 30mg/m2) Data Presented at AACR
19 MM-302 HERMIONE Trial: Potential Registration Path in HER2+ MBC Randomization 1:1 (250 patients) Patient population HER2-positive MBC Anthracycline-naive Prior exposure to pertuzumab and T-DM1 Experimental Arm MM-302 (Q3W) Herceptin (Q3W) Control Arm Chemo of Physician s Choice Herceptin (Q3W) Primary endpoint: Progression- Free Survival Study is designed to support a potential application for accelerated approval in the U.S. and conditional marketing authorization in the E.U. Currently enrolling US sites: Patients with HER2+ locally advanced and metastatic breast cancer No restriction on number of prior lines of therapy Anticipate 70 sites in US, Canada and EU Chemotherapy of physician s choice: one of gemcitabine, capecitabine or vinorelbine Primary endpoint: Hazard Ratio of (8 mo experimental arm vs. 5 mo control arm ) 19
20 # patients MM-121: Addressing ErbB3-Driven Cancers MM-121 is a monoclonal antibody targeting ErbB3 Wholly owned About ErbB3-Driven Cancer Promotes resistance to therapies and worsens patient outcomes Spans many solid tumors Works in conjunction with other pathways Not a traditional oncogenic pathway where it is primary driver of the cancer MM-121 Designed to Target Biomarker Positive (BM+) patients Unmet need BM+ BM- Response Biomarker positive patients appear to respond worse to standard-of-care (SOC) than biomarker negative patients Biomarker positive patients on MM-121 may respond better than biomarker positive patients on SOC alone 20
21 MM-121 PFS Data in Biomarker-Selected Population Comparison of MM-121+SOC vs. SOC for biomarker positive patients Breast cancer Ovarian cancer Lung cancer HRG HIGH * (Archived tissue) HRG HIGH, HER2 LOW (Pre-Rx biopsy) HRG HIGH * (Pre-Rx biopsy) exemestane MM exemestane paclitaxel MM paclitaxel erlotinib MM erlotinib N= N=18 N= N= N=14 N= Time (months) Time (months) Time (months) Study Biomarker Positive Population * HER2 was low in the majority of breast and NSCLC samples, so HER2 measurements were not needed. N HR Prevalence P-value Breast % Ovarian % Lung %
22 Blocking Heregulin is a Large Opportunity in Oncology ER/PR+, HER2- Breast ER-/PR-/HER2+ Breast Triple Negative Breast ER/PR+, HER2+ Breast 45% 59% 49% 53% Bladder Cervical Colorectal Head & Neck 39% 59% 28% 97% Liver Lung, Adeno Lung, Squamous Ovarian 48% 45% 87% 33% Pancreatic Prostate Melanoma Uterine 33% 35% 34% 21% Data from TCGA, based on the observed prevalence of heregulin in ER/PR+, HER2- breast cancer 22
23 MM-121: Targeted Indications Represent Breast cancer ER+, HER2- mbc 326K Patients Annually HRG+ (~45%) MM paclitaxel HRGpaclitaxel MM-121 Eligible Patients HRG+ 36K TNBC HRG+ (~49%) MM chemotherapy chemotherapy HRG+ 6K HRG- Lung cancer EGFR w.t. NSCLC HRG+ (~54%) HRG- MM docetaxel/pemetrexed docetaxel/pemetrexed HRG+ 284K G
24 MM-121 NSCLC Trial Initiated Initiated a Ph2 biomarker-selected clinical trial in patients with heregulin positive non-small cell lung cancer (NSCLC) Merrimack s first study to prospectively select patients based on heregulin status Builds on our learnings from previous MM-121 Ph2 clinical trials completed across lung, ovarian and breast cancers Trial will enroll 120 heregulin positive patients randomized (2:1) to receive either MM-121 plus the investigator s choice of docetaxel or pemetrexed, or the investigator s choice of docetaxel or pemetrexed alone The primary endpoint of the trial is PFS Development plans for breast cancer 24
25 MM-141 Overview Dual antibody inhibitor of IGF-1R and ErbB3 Two unique mechanisms of action: Blocks oncogenic signaling induced by multiple growth factors: IGF-1, IGF-2 and heregulin Degrades receptor complexes that contain IGF-1R and ErbB3 Orphan drug status Wholly owned Global Ph2 trial in patients with metastatic pancreatic cancer who have high serum levels of free IGF-1 Anti-IGF-1R IgG1 antibody (KD=0.3nM) genetically fused with anti-erbb3 antibody fragment (KD=0.9nM) 25
26 MM-141 Ph2 Pancreatic Study Design Front-line Metastatic Pancreatic Cancer Low Free IGF-1 (~104) Observational Group* *OS data collection Screening High Free IGF- 1 (158) Safety Run-in (6-12) Interventional Group** **Mandatory tissue sample for HRG analysis Patients to receive: MM-141 (2.8 grams IV ) or placebo q2w R 1:1 Nab-paclitaxel (125 mg/m 2 IV) and gemcitabine (1000 mg/m 2 IV) weekly for 3 weeks Randomized, double-blind, placebo-controlled Primary endpoint: Progression-free survival HR 0.63, 80% power, p=0.05 Co-primary endpoint: PFS in HRG+ population HR 0.5, 80% power, p=0.05 Secondary endpoint: Overall survival MM nab-paclitaxel and gemcitabine (73) Placebo + nab-paclitaxel and gemcitabine (73) 26
27 MM-398 NDA filing acceptance Upcoming Milestones Initiation of front-line pancreatic and gastric trials Continued commercial preparation ahead of potential post-gem launch MM-121 Planning registration trials in ER/PR+ and TNBC Continued enrollment for Ph2 trial in HRG-positive NSCLC MM-302 Continued enrollment for HERMIONE trial in support of accelerated approval MM-141 Continued enrollment for Ph2 trial in IGF-1-positive 1L pancreatic cancer MM-151 Planning a Ph2 trial in CRC 27
28 Oncology Pipeline Candidate* Design Target Investigational Disease State(s) Preclinical Phase 1 Phase 2 Phase 3 MM-398 Irinotecan liposome injection Topo I/DNA replication Currently under FDA review MM-302 HER2-targeted nanoliposomal doxorubicin Topo II/DNA replication Breast MM-121 Monoclonal antibody ErbB3 NSCLC, Breast MM-111 Bispecific antibody ErbB3 and ErbB2 Gastric MM-141 Bispecific tetravalent antibody IGF-1R and ErbB3 Pancreatic MM-151 Oligoclonal antibody EGFR Colorectal MM-310 Targeted nanoliposome Undisclosed Cancer MM-131 Bispecific antibody HGF-R (c-met) and EpCAM Cancer * None of our product candidates are approved for any indication by the FDA or any other regulatory agency. Nanoliposomes Antibodies 28
A Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationCorporate Overview. September 2018
Corporate Overview September 2018 Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationAnalyst/Investor Call
Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationFormation Biologics. A clinical-stage biopharmaceutical company Lead program projected to achieve clinical validation in 2018
Formation Biologics A clinical-stage biopharmaceutical company Lead program projected to achieve clinical validation in 2018 Formation Biologics Corporate Summary Clinical-stage development company based
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationPhase 2b/3 Topline Trial Results
Phase 2b/3 Topline Trial Results RP-G28 For the Treatment of Lactose Intolerance March 2017 Forward - Looking Statement To the extent that statements contained in this presentation are not descriptions
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationNon-hormonal therapies in advanced breast cancer: new and emerging approaches
Non-hormonal therapies in advanced breast cancer: new and emerging approaches Outline Review goals of treatment Demystify chemotherapy decision making Look at the evidence for improvements over time Discuss
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More information